Nipruss: Uses, Dosage & Side Effects
A direct-acting peripheral vasodilator and nitric oxide donor used as an intravenous infusion for hypertensive emergencies, controlled hypotension during surgery, and acute decompensated heart failure
Nipruss is a brand of sodium nitroprusside, a powerful direct-acting peripheral vasodilator administered as a continuous intravenous infusion. It releases nitric oxide (NO) inside vascular smooth muscle, causing rapid dilatation of both arteries and veins. The result is an immediate, balanced drop in systemic blood pressure and a reduction in cardiac preload and afterload. Nipruss has one of the fastest onsets (within seconds) and shortest durations (1–10 minutes after stopping) of any cardiovascular medicine, which makes it uniquely suitable for moment-to-moment titration in critical care environments. It is approved for the treatment of hypertensive emergencies, for controlled (induced) hypotension during surgery to limit operative bleeding, and as an afterload-reducing agent in acute decompensated heart failure with elevated systemic vascular resistance. Because of its potency and the risk of cyanide and thiocyanate toxicity, Nipruss is restricted to hospital use under continuous, preferably intra-arterial, blood pressure monitoring.
Quick Facts: Nipruss
Key Takeaways
- Nipruss (sodium nitroprusside, ATC C02DD01) is a powerful intravenous vasodilator that lowers blood pressure within 30 seconds and reverses within minutes after the infusion is stopped, making it uniquely titratable for hypertensive emergencies and intraoperative blood pressure control.
- The drug acts by releasing nitric oxide inside vascular smooth muscle, dilating both arteries and veins; this lowers afterload and preload and can also acutely improve cardiac output in decompensated heart failure with high systemic vascular resistance.
- The principal dose-limiting toxicity is cyanide accumulation. Risk increases with infusion rates above 2 micrograms/kg/minute, treatment longer than 24–48 hours, and in patients with hepatic impairment; thiocyanate toxicity becomes important in patients with renal impairment.
- Continuous (ideally intra-arterial) blood pressure monitoring, a precise infusion pump, light-protection of the entire infusion line, and avoidance of bolus dosing are mandatory; abrupt withdrawal can cause rebound hypertension.
- Nipruss is contraindicated in patients with compensatory hypertension (e.g., aortic coarctation, arteriovenous shunts), severe aortic stenosis, congenital optic atrophy, Leber's hereditary optic neuropathy, untreated B12 or folate deficiency, and in conjunction with phosphodiesterase-5 inhibitors or riociguat because of the risk of profound, refractory hypotension.
What Is Nipruss and What Is It Used For?
Nipruss contains sodium nitroprusside dihydrate, an inorganic complex that has been used in clinical medicine since the late 1920s and as an antihypertensive infusion since the 1950s. Each vial contains 60 mg of sterile lyophilized powder that is reconstituted with 5 % glucose (dextrose) solution and then further diluted in an infusion bag immediately before use. The reconstituted solution is light-sensitive and must be protected from light at every step of preparation and administration; the bag and tubing are wrapped in opaque material throughout the infusion.
Sodium nitroprusside is classed as a direct-acting peripheral vasodilator and, more specifically, as a nitric oxide (NO) donor. Once inside the bloodstream, the molecule reacts with red blood cell membranes and intracellular thiols to release nitric oxide. NO is the body’s most important endogenous vasodilator: it activates soluble guanylate cyclase in vascular smooth muscle, raising intracellular cyclic guanosine monophosphate (cGMP) and causing the muscle cells to relax. Because Nipruss dilates both the arterial and the venous side of the circulation in a balanced fashion, it lowers both afterload and preload. This contrasts with pure venodilators (such as nitroglycerin at low doses) that act predominantly on capacitance vessels.
The hemodynamic effect of Nipruss is unparalleled in its speed and reversibility. Blood pressure begins to fall within roughly 30 seconds of starting the infusion, reaches its peak effect at about 2 minutes, and returns to pretreatment values within 1–10 minutes after the infusion is stopped. This pharmacokinetic profile is why Nipruss is favored when minute-to-minute control of arterial pressure is required, for example during surgery on the aorta or the brain, or in the management of an evolving hypertensive emergency where overshoot hypotension could cause stroke or myocardial ischemia.
The clinical indications for Nipruss are concentrated in three areas of critical and perioperative care:
- Hypertensive emergencies and urgencies: Nipruss is one of the original and most studied agents for severely elevated blood pressure with acute end-organ damage. Indications include hypertensive encephalopathy, acute aortic dissection (in combination with a beta-blocker to control heart rate and shear stress), severe pre-eclampsia/eclampsia (when other agents have failed), perioperative hypertensive crisis, and severe hypertension complicating intracerebral hemorrhage. Modern guidelines, including those of the European Society of Cardiology and the American Heart Association, list sodium nitroprusside as a recommended option, although newer agents such as nicardipine, clevidipine, and labetalol are often preferred when available because of their more favorable safety profiles.
- Controlled (induced, deliberate) hypotension during surgery: By transiently lowering mean arterial pressure to a defined target, Nipruss reduces operative bleeding and improves the surgical field. It is used in selected neurosurgical procedures (clipping of cerebral aneurysms, posterior fossa surgery), major orthopedic operations (such as spine surgery and total hip replacement), middle-ear and reconstructive plastic surgery, and certain cardiac and vascular procedures. The technique requires careful patient selection, rigorous monitoring, and clear pre-defined safety limits.
- Acute decompensated heart failure: In patients with low cardiac output and elevated systemic vascular resistance, especially when the underlying mechanism is hypertensive cardiomyopathy or acute mitral or aortic regurgitation, Nipruss can rapidly reduce afterload, increase stroke volume, and improve forward flow. It is typically used in coronary care or intensive care units with invasive hemodynamic monitoring (arterial line and, in selected cases, pulmonary artery catheter).
- Less common indications: In selected centers, sodium nitroprusside has been used to manage acute aortic regurgitation, ergotamine-induced peripheral ischemia, autonomic dysreflexia in patients with high spinal cord injury, and to improve graft function during organ transplantation. These uses lie outside the marketed indications of most national labels and are decided on a case-by-case basis.
Despite the introduction of newer intravenous antihypertensives (clevidipine, nicardipine, esmolol, fenoldopam), Nipruss retains an important niche because no other agent matches its combination of speed, potency, balanced arterial and venous dilatation, and ultra-short half-life. In situations where every second of blood pressure control matters – intraoperatively, in evolving hypertensive emergencies, or when acute afterload reduction is essential – sodium nitroprusside remains an invaluable tool when used by experienced clinicians in a properly monitored environment.
What Should You Know Before Receiving Nipruss?
Contraindications
Sodium nitroprusside has a number of strict contraindications that reflect its mechanism of action and toxicity profile. These should be reviewed before any infusion is started.
- Hypersensitivity: Known hypersensitivity to sodium nitroprusside, to any of the cyanide-releasing complexes, or to any of the excipients in the product.
- Compensatory hypertension: Conditions in which a high blood pressure is necessary to maintain perfusion downstream of a structural obstruction, such as aortic coarctation or arteriovenous shunting. Lowering blood pressure in these patients can produce critical organ ischemia.
- Severe aortic stenosis or other fixed-output states: Patients dependent on a high systemic vascular resistance to maintain coronary perfusion may decompensate catastrophically if afterload is reduced.
- Acute heart failure with low systemic vascular resistance (for example, distributive shock).
- Congenital (Leber’s) optic atrophy and tobacco amblyopia: These patients have a deficiency in the cyanide-detoxifying enzyme rhodanese and are at very high risk of irreversible optic nerve damage.
- Untreated vitamin B12 (cyanocobalamin) or folate deficiency: Vitamin B12 is required for cyanide detoxification.
- Concomitant use of phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil, avanafil) or guanylate cyclase stimulators (riociguat, vericiguat). The combined effect on the NO-cGMP pathway can cause profound, refractory hypotension.
- Severe hepatic impairment (relative contraindication): the liver is essential for cyanide detoxification through rhodanese.
Warnings and Precautions
Every nitroprusside molecule that is metabolized releases five cyanide ions. Most of these are detoxified by hepatic rhodanese (using thiosulfate as a sulfur donor) to thiocyanate, which is excreted by the kidneys. Cyanide accumulation can occur with infusion rates above 2 micrograms/kg/minute, with prolonged infusions (typically >24–48 hours), or in patients with hepatic impairment. Early signs include unexplained metabolic acidosis with elevated lactate, narrowing of the venous-arterial oxygen difference, agitation, and tachyphylaxis (loss of antihypertensive effect). Thiocyanate accumulates in renal impairment and presents with fatigue, nausea, hyperreflexia, confusion, psychosis, and seizures. Both should be actively monitored for and managed with prompt cessation of the infusion and, if necessary, antidotal therapy (sodium thiosulfate, hydroxocobalamin, sodium nitrite).
Before and during treatment with Nipruss, the medical team should be aware of a number of additional precautions:
- Excessive hypotension: Even small dose changes can produce dramatic falls in blood pressure within seconds. The infusion must be delivered through a precise pump and titrated against continuous, preferably intra-arterial, pressure measurement. A predefined lower limit for mean arterial pressure must be agreed in advance, and the rate must never be increased without confirming the current blood pressure.
- Increased intracranial pressure: Sodium nitroprusside dilates cerebral vessels and may increase intracranial pressure, which can be detrimental in patients with traumatic brain injury, intracranial hemorrhage, or space-occupying lesions. Other agents are generally preferred in this setting, or Nipruss is used only when intracranial pressure can be monitored.
- Coronary “steal”: By dilating non-stenotic coronary arterioles preferentially, sodium nitroprusside may divert blood away from ischemic myocardium. It should therefore be used with caution in patients with active myocardial ischemia or recent myocardial infarction, and is not first-line for hypertensive emergency in this context.
- Pulmonary disease: Sodium nitroprusside can blunt hypoxic pulmonary vasoconstriction, worsening ventilation-perfusion mismatch and oxygenation in patients with significant lung disease.
- Hypothyroidism: Thiocyanate inhibits iodide uptake by the thyroid gland; patients with hypothyroidism are more sensitive and may decompensate during prolonged infusions.
- Renal impairment: Although the parent drug is metabolized rapidly, thiocyanate is renally excreted and accumulates in renal failure, with toxic plasma levels typically considered to start above 60 mg/L. Hemodialysis effectively removes thiocyanate.
- Hepatic impairment: The liver is required for cyanide detoxification; cyanide accumulation occurs more rapidly in cirrhosis or acute liver failure.
- Methemoglobinemia: Prolonged or high-dose infusions can convert hemoglobin to methemoglobin, reducing oxygen carrying capacity. Suspected when oxygen saturation by pulse oximetry remains low despite adequate ventilation; methylene blue is the antidote.
- Rebound hypertension: Abrupt cessation of the infusion can cause a rebound rise in blood pressure as the very short half-life means the antihypertensive effect disappears within minutes. The infusion should always be tapered, and an oral or longer-acting parenteral antihypertensive started in parallel.
- Solution stability: Sodium nitroprusside solutions are extremely sensitive to light and to a lesser extent to temperature. The reconstituted solution is faintly brown; if it becomes blue, green, or dark red, decomposition has occurred and the solution must be discarded.
Pregnancy and Breastfeeding
Sodium nitroprusside crosses the placenta and may produce cyanide accumulation in the fetus, which has limited capacity to detoxify cyanide. It is therefore generally avoided during pregnancy. In the rare event of a maternal hypertensive emergency that does not respond to first-line agents (labetalol, hydralazine, or nicardipine), Nipruss may be used briefly when the maternal benefit clearly outweighs the fetal risk. The lowest effective infusion rate for the shortest possible time should be chosen, ideally in the immediate peripartum period after the fetus has been delivered or when delivery is imminent.
It is not known whether sodium nitroprusside or its metabolite thiocyanate is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants, and because thiocyanate has a long half-life, breastfeeding should be interrupted during the infusion and for at least 24 hours after the infusion ends.
Children and Adolescents
Sodium nitroprusside is used in pediatric intensive care for the same indications as in adults – hypertensive emergencies, controlled hypotension during surgery (notably scoliosis correction and craniofacial surgery), and acute heart failure. Children appear to detoxify cyanide as efficiently as adults but should be monitored with the same vigilance. Doses are calculated by body weight and should start at 0.3–0.5 micrograms/kg/minute and be titrated upward.
Elderly Patients
Older patients are more sensitive to the hypotensive effects of sodium nitroprusside because of reduced baroreflex responsiveness and a higher prevalence of underlying cardiac, renal, and cerebrovascular disease. Lower starting doses (0.1–0.3 micrograms/kg/minute) and slower titration are recommended, with particular attention to avoiding overshoot hypotension that may precipitate stroke or myocardial ischemia.
Driving and Operating Machinery
Because Nipruss is administered only as an inpatient infusion in critical care, patients are not able to drive or operate machinery during treatment. Following the infusion, the drug is completely cleared within minutes and there is no residual cognitive effect attributable to the medicine itself, although patients should not drive after discharge from a hypertensive emergency or surgery until cleared by their treating physician.
How Does Nipruss Interact with Other Drugs?
Sodium nitroprusside is not metabolized by hepatic cytochrome P450 enzymes, so classical pharmacokinetic interactions are uncommon. The clinically important interactions are pharmacodynamic: any agent that lowers blood pressure, dilates blood vessels, or interferes with the nitric oxide / cGMP signaling pathway will potentiate the action of Nipruss and may produce profound hypotension. Always inform the prescribing team about every medication, supplement, or recreational substance the patient is using.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) | Synergistic accumulation of cGMP in vascular smooth muscle, profound and prolonged hypotension | Contraindicated – do not initiate Nipruss within 24 hours of sildenafil/vardenafil or 48 hours of tadalafil; risk of refractory hypotension and death |
| Soluble guanylate cyclase stimulators (riociguat, vericiguat) | Additive activation of the same pathway as nitric oxide donors | Contraindicated – risk of severe systemic and pulmonary hypotension |
| Other intravenous vasodilators (nitroglycerin, hydralazine, nicardipine, clevidipine) | Additive blood pressure lowering and reflex tachycardia | Avoid routine combination; if unavoidable, halve doses and titrate against continuous arterial pressure |
| Volatile anesthetics (sevoflurane, isoflurane, desflurane) | Marked potentiation of vasodilatation; reduced sympathetic tone | Use lower starting doses of Nipruss during general anesthesia; close pressure monitoring required |
| Ganglion-blocking agents (e.g., trimetaphan) | Severe hypotension by simultaneous blockade of sympathetic outflow and vasodilatation | Generally avoid; specialist use only |
| Negative inotropes (beta-blockers in high dose, non-dihydropyridine calcium-channel blockers) | Reduced compensatory tachycardia and contractility, increased risk of cardiogenic shock if afterload reduction is excessive | Useful combination in aortic dissection (where heart-rate control is required) but otherwise titrate carefully |
Minor and Other Notable Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Opioid analgesics, benzodiazepines, propofol | Additive vasodilatation and sympathetic depression | Common combination in critical care; titrate carefully and treat hypovolemia first |
| Diuretics | Additive blood pressure reduction; risk of hypotension if intravascular volume is depleted | Optimize volume status before initiating Nipruss |
| Sympathomimetics (norepinephrine, phenylephrine, ephedrine) | Antagonism of vasodilatation; useful for treating overshoot hypotension | Should be immediately available at the bedside whenever Nipruss is infused |
| Iodine-containing contrast media | Possible additive vasodilatation and renal stress | Monitor pressure and renal function during procedures involving contrast |
| Alcohol and recreational drugs (cocaine, MDMA, methamphetamine) | Unpredictable hemodynamic interactions; rebound hypertension on washout of stimulants | Document recent intake; consider beta-blockade or alternative antihypertensives in stimulant intoxication |
| Solutions containing other drugs | Sodium nitroprusside is incompatible with most other intravenous medications | Infuse via a dedicated line; do not co-infuse other drugs through the same access |
Sodium nitroprusside is also incompatible with several intravenous solutions and additives. The reconstituted product should be diluted only in 5 % glucose (dextrose) solution. Avoid normal saline as the diluent unless local protocols specifically allow it. Do not add other medicines, electrolytes, or buffers to the infusion bag.
What Is the Correct Dosage of Nipruss?
Sodium nitroprusside has one of the most demanding dosing requirements in clinical pharmacology. The therapeutic window is narrow, the response is immediate, and the consequences of error are severe. For these reasons, every infusion must be calculated by weight, prepared in a standardized concentration, delivered through a dedicated line on a precision infusion pump, and adjusted only against continuous, preferably intra-arterial, pressure measurement. The infusion bag and tubing must be wrapped in opaque material to protect the solution from light.
Preparation of the Infusion
The 60 mg vial of Nipruss is reconstituted with the diluent supplied or with a small volume of 5 % glucose (dextrose). The reconstituted concentrate is then added to a 250 mL or 500 mL bag of 5 % glucose to give a final concentration that is convenient for the chosen infusion pump (commonly 50, 100, or 200 micrograms/mL). The bag must be wrapped in aluminum foil or an opaque sleeve immediately after preparation. Tubing should also be light-protected. Do not use the solution if it has changed color from faintly brown to blue, green, or dark red, which indicates degradation and cyanide release.
Dosing by Indication
Adults – Hypertensive Emergency
Initial rate: 0.3–0.5 micrograms/kg/minute by continuous IV infusion.
Titration: Increase by 0.5 micrograms/kg/minute every 3–5 minutes until the desired blood pressure is achieved.
Usual range: 0.5–6 micrograms/kg/minute. Maximum: 10 micrograms/kg/minute (and only briefly).
Target: Reduce mean arterial pressure by no more than 20–25 % within the first hour, then a further reduction toward 160/100–110 mmHg over the following 2–6 hours. More aggressive reduction increases the risk of stroke and myocardial ischemia (except in aortic dissection, where lower targets may be needed).
Adults – Controlled Hypotension During Surgery
Initial rate: 0.25–0.5 micrograms/kg/minute under general anesthesia.
Titration: Up- or down-titrate every 1–2 minutes against continuous arterial pressure to the surgeon-agreed mean arterial pressure target.
Duration: Limited to the shortest time necessary; typically discontinued before hemostasis is achieved to allow safe blood pressure recovery.
Adults – Acute Decompensated Heart Failure
Initial rate: 0.1–0.3 micrograms/kg/minute, with invasive hemodynamic monitoring (arterial line; pulmonary artery catheter where available).
Titration: Increase by 0.1–0.2 micrograms/kg/minute every 5–10 minutes against systemic vascular resistance, cardiac output, and arterial pressure.
Usual range: 0.3–3 micrograms/kg/minute.
Children and Adolescents
Initial rate: 0.3–0.5 micrograms/kg/minute.
Titration: Upward in steps of 0.5 micrograms/kg/minute every 5 minutes against continuous arterial pressure.
Maximum: 8 micrograms/kg/minute (not sustained); same cyanide toxicity precautions as in adults apply.
Elderly Patients
Initial rate: 0.1–0.3 micrograms/kg/minute.
Titration: More cautious titration with smaller increments and longer intervals; lower target blood pressure reductions to avoid cerebral hypoperfusion.
Renal or Hepatic Impairment
No formal pharmacokinetic dose reduction is defined, but infusion rates above 2 micrograms/kg/minute and infusions longer than 24 hours should be avoided when possible. Plasma thiocyanate concentrations should be monitored when treatment exceeds 24–48 hours; values above 60 mg/L are considered toxic. Consider early hemodialysis in renal failure.
How Nipruss Is Administered
- Always via continuous intravenous infusion through a precision pump; never as a bolus or rapid push.
- Through a dedicated central or large peripheral vein; do not co-infuse with other drugs.
- Continuous arterial blood pressure monitoring is the standard of care; non-invasive pressure measurement is acceptable only briefly while an arterial line is being placed.
- Light-protect the bag and the tubing throughout the infusion.
- Discard any unused solution after 24 hours.
Missed Dose
Because Nipruss is given only as a continuous inpatient infusion under direct supervision, “missed dose” in the conventional sense does not apply. If the infusion is interrupted, blood pressure will rise back toward baseline within minutes, sometimes overshooting (rebound hypertension); in such cases, an alternative antihypertensive (oral or longer-acting parenteral) should already be in place, or the infusion should be restarted promptly at the previous rate.
Overdose
Overdose with sodium nitroprusside has two distinct presentations: acute, profound hypotension and metabolic toxicity from cyanide and thiocyanate accumulation.
- Excessive hypotension: Stop the infusion immediately. The blood pressure usually recovers within 1–10 minutes because of the very short half-life. If hypotension persists, place the patient supine, raise the legs, infuse intravenous fluids, and use a vasopressor (norepinephrine, phenylephrine) if needed.
- Suspected cyanide toxicity: Stop the infusion. Administer 100 % oxygen. Specific antidotes include hydroxocobalamin 5 g IV (which binds cyanide to form non-toxic cyanocobalamin), sodium thiosulfate 12.5 g IV (which provides a sulfur donor for endogenous detoxification), and, in severe cases, sodium nitrite 300 mg IV (which generates methemoglobin to bind cyanide). Co-administration of sodium thiosulfate with prolonged sodium nitroprusside infusions has been used prophylactically in some protocols.
- Thiocyanate toxicity: Stop the infusion and consider hemodialysis, which efficiently removes thiocyanate.
Nipruss is always prepared and administered by trained healthcare professionals in an intensive care unit, operating room, coronary care unit, or emergency department. Patients never self-administer this medication, and it is not available for community or outpatient use.
What Are the Side Effects of Nipruss?
Like all medicines, Nipruss can cause side effects, although the majority of patients receive it for short periods under intensive monitoring and recover without sequelae. Most adverse effects are pharmacological extensions of its potent vasodilator action and resolve within minutes when the infusion is reduced or stopped. The most clinically important adverse effects relate to cyanide and thiocyanate accumulation and to the consequences of excessive blood pressure reduction.
Side Effects by Frequency
Very Common
May affect more than 1 in 10 people
- Excessive hypotension (especially with rapid up-titration)
- Reflex tachycardia and palpitations
- Headache (often throbbing, due to cerebral vasodilatation)
- Nausea and vomiting
- Sweating, flushing
- Restlessness, anxiety, apprehension
- Abdominal pain or cramping
- Dizziness, light-headedness on dose increases
Common
May affect up to 1 in 10 people
- Bradycardia (occasionally seen at high infusion rates)
- Substernal chest discomfort or angina-like pain
- Muscle twitching
- Increased intracranial pressure
- Worsening of ventilation-perfusion mismatch and hypoxemia
- Local irritation or inflammation at the infusion site
- Rebound hypertension on abrupt discontinuation
- Mild metabolic acidosis
- Tachyphylaxis (loss of response despite increasing dose)
Uncommon
May affect up to 1 in 100 people
- Methemoglobinemia (with long, high-dose infusions)
- Hypothyroidism with prolonged use (thiocyanate effect on iodide uptake)
- Vomiting, ileus
- Transient elevation of liver enzymes
- Marked diaphoresis with cool, clammy skin
- Acute coronary “steal” in patients with severe coronary artery disease
Rare
May affect up to 1 in 1,000 people
- Cyanide toxicity (severe metabolic acidosis, narrowed venous-arterial oxygen difference, altered consciousness, seizures, cardiovascular collapse)
- Thiocyanate toxicity (fatigue, hyperreflexia, confusion, psychosis, seizures, coma) – especially in renal impairment or with prolonged infusion
- Optic atrophy and visual disturbance (in patients with predisposition)
- Severe rebound hypertension precipitating heart failure or stroke
- Pancreatitis
- Hypersensitivity reactions (rash, urticaria)
Not Known
Frequency cannot be estimated from available data
- Anaphylactoid reactions
- Skin necrosis at the infusion site after extravasation
- Permanent neurological injury after severe or unrecognized cyanide toxicity
- Fetal cyanide accumulation when used in pregnancy
The most reliable early sign of cyanide accumulation is the development of an unexplained metabolic acidosis with an elevated arterial lactate, often accompanied by a sudden need to increase the infusion rate to maintain the same antihypertensive effect (tachyphylaxis). Mixed venous oxygen saturation may rise because tissues can no longer use oxygen. The combination of these findings during a sodium nitroprusside infusion should trigger immediate cessation of the drug and consideration of antidotal therapy.
Effects on Laboratory Tests
During treatment, the medical team will follow arterial pH and lactate (signs of cyanide toxicity), serum electrolytes, methemoglobin (in long infusions, by co-oximetry), thyroid function (in infusions lasting more than a few days), and plasma thiocyanate concentration if the infusion exceeds 24–48 hours or if renal function is impaired.
Reporting Adverse Reactions
If you or someone you care for experiences any side effect, including any not listed above, report it to your doctor, nurse, or pharmacist. Suspected adverse drug reactions can also be reported to your national pharmacovigilance authority (for example, the EMA EudraVigilance system in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom). Reporting helps regulators monitor the safety of all medicines in real-world use.
How Should Nipruss Be Stored?
Nipruss is supplied as a sterile lyophilized powder in a single-use vial. Storage is normally handled by the hospital pharmacy and the bedside nursing team; patients do not store this medicine themselves. The following principles apply at every stage from delivery to administration:
- Unopened vials: Store below 25°C in the original carton to protect from light. Do not freeze. Do not use after the expiry date printed on the label.
- After reconstitution: The reconstituted concentrate and the further-diluted infusion bag are extremely light-sensitive. Wrap the bag and the infusion tubing in aluminum foil or a dedicated opaque sleeve immediately after preparation and keep them light-protected throughout the infusion.
- Solution color: A freshly prepared solution is faintly brown. If the color changes to blue, green, or dark red, decomposition has occurred (with the release of additional cyanide) and the solution must be discarded.
- Stability: Use within 24 hours of preparation. Discard any solution remaining at the end of the infusion or after 24 hours.
- Compatibility: Dilute only in 5 % glucose (dextrose). Do not add other medicines, electrolytes, or buffers to the bag, and do not co-infuse other drugs through the same line.
- Inspection: Always inspect visually for particles or discoloration before administration.
Unused medicine and contaminated infusion sets must be disposed of according to local hazardous-waste protocols. Never dispose of pharmaceutical products via wastewater or household waste – this protects both patients and the environment.
What Does Nipruss Contain?
Active Substance
The active substance is sodium nitroprusside dihydrate, also known chemically as sodium nitroferricyanide dihydrate (Na₂[Fe(CN)₅NO]·2H₂O). Each single-use vial contains 60 mg of sodium nitroprusside dihydrate as a sterile lyophilized powder for reconstitution and dilution.
Inactive Ingredients (Excipients)
The lyophilized powder formulation typically contains no other excipients. The recommended diluent is 5 % glucose (dextrose) injection. Specific excipient and diluent recommendations may vary slightly between marketed formulations and national authorizations; consult the local Summary of Product Characteristics (SmPC) or package leaflet for the exact composition of the product in use.
Appearance and Pack Sizes
Nipruss appears as a sterile, almost white to slightly red-brown lyophilized powder in a single-use glass vial. After reconstitution with 5 % glucose, the solution is faintly brown and clear, and free from visible particles. Any discoloration to blue, green, or dark red indicates degradation, and the solution must not be used. Pack sizes vary by country; not all pack sizes may be marketed locally.
Marketing Authorization and Manufacturer
The marketing authorization holder and the manufacturer of Nipruss vary by country. Equivalent products containing sodium nitroprusside are marketed worldwide under several other brand names, including Nipride, Nipride RTU, and Nitropress. Always check the marketed name, holder, and exact strength on the carton and vial before use.
Frequently Asked Questions About Nipruss
Nipruss (sodium nitroprusside) is an intravenous vasodilator used in three principal clinical situations: hypertensive emergencies (to lower blood pressure rapidly and prevent end-organ damage), controlled hypotension during surgery (to reduce intraoperative bleeding), and acute decompensated heart failure with elevated systemic vascular resistance (to acutely reduce afterload and improve cardiac output). It is restricted to intensive care units, operating rooms, and emergency departments because of its potency and the need for continuous monitoring.
Nipruss is one of the most potent and fastest-acting blood-pressure-lowering medicines available. Even small dosing errors can produce dangerous hypotension within seconds. Continuous (preferably arterial) blood pressure monitoring is mandatory, and the infusion must be delivered through a precise pump. The drug also releases cyanide as it works, which the body must detoxify; this requires monitoring of acid-base status and clinical signs of cyanide toxicity. For all of these reasons, Nipruss is restricted to intensive care units, operating rooms, emergency departments, and similar settings with continuous monitoring and immediate access to resuscitation.
The most serious adverse effects are excessive hypotension (which can cause stroke, myocardial infarction, or cardiac arrest), cyanide toxicity (with metabolic acidosis, tachyphylaxis, altered mental status, and ultimately cardiovascular collapse), thiocyanate toxicity in renal impairment (fatigue, nausea, hyperreflexia, confusion, psychosis, seizures), methemoglobinemia (which reduces oxygen carrying capacity), and rebound hypertension if the infusion is stopped abruptly. Treatment in a closely monitored environment allows these complications to be detected and managed immediately.
Nipruss has one of the fastest onsets and shortest durations of any intravenous medicine. After the infusion is started, blood pressure begins to fall within 30 seconds, with maximum effect within about 2 minutes. When the infusion is stopped, blood pressure returns to pretreatment levels within 1 to 10 minutes. This extreme titratability is why it is favored in operating rooms and intensive care units, where moment-to-moment control of blood pressure is essential.
Sodium nitroprusside crosses the placenta and can produce cyanide accumulation in the fetus, which has limited capacity to detoxify cyanide. It is therefore generally avoided during pregnancy. However, in the rare circumstance of a severe maternal hypertensive emergency that does not respond to first-line agents (such as labetalol, hydralazine, or nicardipine), Nipruss may be used briefly when the maternal benefit clearly outweighs the fetal risk. The lowest effective dose for the shortest possible time should be used, ideally in the immediate peripartum period. Breastfeeding should be interrupted during the infusion and for at least 24 hours afterward.
Sodium nitroprusside is highly photosensitive. When exposed to light, the molecule decomposes, releasing additional cyanide and forming inactive aquopentacyanoferrate, which can give the solution a blue, green, or dark red discoloration. A discolored solution must not be used. To prevent decomposition, the infusion bag and tubing must be wrapped in opaque material (typically aluminum foil or a dedicated light-protective sleeve) immediately after dilution and throughout the infusion. The reconstituted solution should be used within 24 hours and any unused portion discarded.
Each sodium nitroprusside molecule that is metabolized releases five cyanide ions. Most are detoxified in the liver by the enzyme rhodanese (which uses thiosulfate as a sulfur donor) to thiocyanate, which is then excreted by the kidneys. When the infusion rate is too high, when treatment is prolonged, or when liver function is poor, cyanide can accumulate. Early signs include unexplained metabolic acidosis with elevated lactate, narrowing of the venous-arterial oxygen difference, agitation, and loss of antihypertensive response (tachyphylaxis). Treatment is to stop the infusion immediately and administer specific antidotes – hydroxocobalamin, sodium thiosulfate, and, in severe cases, sodium nitrite – together with 100 % oxygen and supportive care.
Sodium nitroprusside lowers blood pressure by releasing nitric oxide, which raises cyclic guanosine monophosphate (cGMP) inside vascular smooth muscle. Phosphodiesterase-5 (PDE5) inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil prevent the breakdown of cGMP. When the two are given together, cGMP rises to extreme levels and produces profound, prolonged, and sometimes refractory hypotension that may cause myocardial infarction, stroke, or death. The same applies to soluble guanylate cyclase stimulators (riociguat, vericiguat). Nipruss should not be initiated within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil. Always check the patient’s recent medication history before starting an infusion.
References
- European Medicines Agency (EMA) and national competent authorities. Sodium nitroprusside (Nipruss) – Summary of Product Characteristics. Last updated 2024. Available at EMA and national medicines agency websites.
- U.S. Food and Drug Administration (FDA). Nitropress (sodium nitroprusside) Prescribing Information. Available from: FDA Drug Label Database.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the Management of Arterial Hypertension. J Hypertens. 2023;41(12):1874–2071. doi:10.1097/HJH.0000000000003480.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13–e115. doi:10.1161/HYP.0000000000000065.
- van den Born BJH, Löwenberg EC, van der Hoeven NV, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens. 2011;29(5):922–927. doi:10.1097/HJH.0b013e328344fc55.
- Hottinger DG, Beebe DS, Kozhimannil T, Prielipp RC, Belani KG. Sodium nitroprusside in 2014: a clinical concepts review. J Anaesthesiol Clin Pharmacol. 2014;30(4):462–471. doi:10.4103/0970-9185.142799.
- Friederich JA, Butterworth JF. Sodium nitroprusside: twenty years and counting. Anesth Analg. 1995;81(1):152–162. doi:10.1097/00000539-199507000-00031.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895–e1032. doi:10.1161/CIR.0000000000001063.
- Hall VA, Guest JM. Sodium nitroprusside-induced cyanide intoxication and prevention with sodium thiosulfate prophylaxis. Am J Crit Care. 1992;1(2):19–25.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- British National Formulary (BNF). Sodium nitroprusside. London: BMJ Group and Pharmaceutical Press; updated 2025. Available at bnf.nice.org.uk.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in cardiology, anesthesiology, intensive care, and clinical pharmacology.
Medical Content
iMedic Cardiology & Critical Care Editorial Team – specialist physicians with clinical experience in hypertensive emergencies, perioperative blood pressure management, and acute heart failure
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, ESC, ESH, and AHA/ACC guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, vasoactive infusions, antidote therapy, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.